Fortress Biotech Inc
F:CNB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fortress Biotech Inc
F:CNB
|
US |
|
AJ Bell PLC
LSE:AJB
|
UK |
|
Qiagen NV
NYSE:QGEN
|
NL |
|
S
|
Scentre Group
SWB:59S
|
AU |
|
C
|
CNH Industrial NV
LSE:0QGU
|
UK |
Fortress Biotech Inc
Fortress Biotech is a biopharmaceutical company that builds a portfolio of drug assets through a network of subsidiaries. It looks for medicines that are already in development or on the market, then helps finance, develop, and in some cases commercialize them. Its focus is on areas such as cancer, skin disease, and other specialty conditions where small, targeted drug businesses can be developed separately. The company makes money in a few ways: sales of approved products through its operating subsidiaries, licensing and collaboration payments from partners, and milestone or royalty income tied to drug development and commercialization. Its customers are mainly doctors, hospitals, pharmacies, and other healthcare providers that prescribe or dispense the medicines, while its partners include larger drug companies and research collaborators. What makes Fortress different is that it does not behave like a single-drug biotech. It acts more like a biotech builder, owning and supporting multiple separate programs and companies under one roof. That structure lets it spread risk across several medicines and gives it a role in the value chain as both an investor in drug development and a commercial owner of certain specialty therapies.
Fortress Biotech is a biopharmaceutical company that builds a portfolio of drug assets through a network of subsidiaries. It looks for medicines that are already in development or on the market, then helps finance, develop, and in some cases commercialize them. Its focus is on areas such as cancer, skin disease, and other specialty conditions where small, targeted drug businesses can be developed separately.
The company makes money in a few ways: sales of approved products through its operating subsidiaries, licensing and collaboration payments from partners, and milestone or royalty income tied to drug development and commercialization. Its customers are mainly doctors, hospitals, pharmacies, and other healthcare providers that prescribe or dispense the medicines, while its partners include larger drug companies and research collaborators.
What makes Fortress different is that it does not behave like a single-drug biotech. It acts more like a biotech builder, owning and supporting multiple separate programs and companies under one roof. That structure lets it spread risk across several medicines and gives it a role in the value chain as both an investor in drug development and a commercial owner of certain specialty therapies.
Revenue Growth: Journey Medical reported Q3 revenue of $17.6 million, up 21% year-over-year, driven by the launch of EMROSI.
EMROSI Launch: EMROSI contributed $4.9 million in Q3, with a 75% increase from Q2 and prescription volume more than doubling sequentially.
Margin Trends: Gross margin improved sequentially in 2025, reaching 67.4% in Q3, up from 63.5% in Q1, despite a year-over-year decline due to prior period adjustments.
Profitability Outlook: EBITDA loss narrowed quarter-over-quarter, and management expects to achieve sustainable EBITDA positivity in Q4.
Access Expansion: EMROSI now has contracts with 2 of the 3 major GPOs, with broader health plan coverage expected to increase in 2026, reducing reliance on co-pay assistance.
Product Portfolio: Legacy products were flat sequentially but down 16% year-over-year, mainly due to Accutane generic competition, though Accutane appears to have stabilized.
Physician Adoption: Unique EMROSI prescribers grew to over 2,700, up about 50% since last quarter, with management aiming to increase both breadth and depth of prescribing.
